None listed
Conditions
Brief summary
Ureteral stents can often cause significant post-stent morbidity and discomfort. There are many different brands of stents currently available but there is no evidence that there is any difference between them in terms of stent related symptoms. This study aims to compare the Cook Universa Soft and Bard Inlay Optima Stents post-op stent related symptoms (SRS) in relation to the validated Ureteral Stent Symptom Questionnaire. This comparison will be through a randomized double-blinded trial of the two different brands of stents.
Interventions
This study is comparing the Bard Inlay Optima and Cook Universa Soft Ureteral Stents when used for stent insertion for upper urinary tract calculi or large stones before lithotripsy or after ureteroscopy at the Townsville and Toowomba Hospital. Materials: The materials being used will be first and foremost the two aforementioned stents – the Bard Inlay Optima and Cook Universa Soft Ureteral Stents. Both will be inserted as part of the clinical trial by urological registrars or consultant surgeons at the Townsville and Toowomba Hospital. Their post operative stent symptoms will be measured through two methods. First, the Ureteral Stent Symptoms Questionnaire (USSQ) – a validated questionnaire produced by the Bristol Urological Institute to measure post-operative stent related symptoms. ] Procedures: Following patient consenting for the procedure, patient’s will have the stent they are randomized to (either Bard Inlay Optima or Cook Universa Soft), inserted by the urologist registrar or consultant as stated above. Intra-operatively, multi-length double J stents of either the Bard Inlay Optima (4.7 French) and Cook Universa Soft (5 french) variety will be inserted. Post operatively, patients will be provided with appropriate medications for stent pain if desired. Patients will be then receive a phone call from the Principal Investigator (PI) at 1 and 3 weeks after insertion and surveyed as per the USSQ. We would note that throughout this the PI conducting the survey will be blinded to which stent was inserted in the patient. All data will be recorded in a relevant data collection tool in which data pertaining to the date of procedure, patient characteristics, USSQ score and post operative opiod use for SRS. Early stent removal will be defined as having the stent removed prior to 3 weeks. Who: The intervention will be delivered by a recognized urology registrar or consultant urologist at the Townsville or Toowoomba Hospital. The survey will be conducted by the Principal Investigator, a doctor with experience in urology. Mode of Delivery: The surveys above will be delivered via telephone surveys delivered individually to each patient with the stent inserted. Number of times: The intervention (the stenting) will only be delivered once however patients will be followed up at two points – 1 week and 3 weeks post operatively. Location: The intervention will occur at the Townsville, Toowoomba and Redcliffe Hospital Intervention Adherence or Fidelity: Patients will be followed up if they have early stent removal and this will be documented accordingly in the data collection tool. A data monitoring board will be set up for the study to ensure randomization and protocol is being carried out as appropriate.
Sponsors
Study design
Eligibility
Inclusion criteria
Setting and Target Participants: All consenting patients receiving stent insertion for upper urinary tract calculi, large stones before lithotripsy or after ureteroscopy or Pelvo-Ureterojunction Obstruction at the Townsville and Towoomba Hospital between the 1st of August 2017 to the 1st of August 2019. Inclusion criteria • Patients undergoing unilateral retrograde ureteral stent placement • Age – over 18 years
Exclusion criteria
• Untreated urinary tract infections • Undergoing additional transurethral procedures or bilateral calculi • All patients with obstructive uropathy secondary to malignancy • Anatomical deformities of the urinary tract such as Duplex or Complete Duplex Ureters • Pelvic radiation therapy • Current bladder cancer • Long term indwelling ureteric stents • Indwelling catheter (IDC) or Suprapubic Catheter (SPC) dependent • Performing clean intermittent self-catheterisation • Ureteric stent present in last 31 days or if the patient has been previously recruited for the study • Post-operative sepsis • Patients who do not speak English – USSQ version used has been only validated in English • Patient’s with cognitive impairments or intellectual disabilities preventing them from comprehending or answering the USSQ • Pregnant women • Patients with history of: - Chronic pain - Bladder or prostate surgeries including: o Radical Prostatectomy o Partial cystectomy o Diveritculectomy o Ureter reimplant o Other significant Bladder Surgeries - Neurogenic bladder - Chronic alpha-blocker medication, opioid analgesia or anticholinergics - Spinal cord injury